Neuralstem, Inc. (NASDAQ:CUR) shares are climbing nearly 6% after announcing this morning it had entered into an official agreement with Tianjin Pharmaceutical Holding Group, …
Pfizer will acquire Medivation for $81.50 per share in cash- an offer unlikely to be bested, says Brean Capital
In a research report released Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR), while slashing the …
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a …
In a research note issued yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) with a price target of …
In a research report issued Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), and reduced …
Keryx Biopharmaceuticals (NASDAQ:KERX) shares are tumbling nearly 12% in early trading, following an impending supply interruption for key pipeline drug, Auryxia, a drug created …
In a research report issued Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR), with an $8.
In a research report issued Thuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a …
In a research report issued Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), while slashing the price …
